Natco Pharma Limited has informed the Exchange regarding a press release dated March 03, 2026, titled "NATCO announces launch of Pomalidomide Capsules (generic of Pomalyst®) in the U.S. market".
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma, along with partner Breckenridge Pharmaceutical, has launched Pomalidomide Capsules — a generic version of Celgene's Pomalyst® — in the U.S. market. The drug is used to treat multiple myeloma and AIDS-related Kaposi sarcoma and is available in 1mg, 2mg, 3mg, and 4mg strengths. The branded product had estimated U.S. sales of USD 3.2 billion over the 12 months ending September 2025. Natco believes it has 180 days of shared exclusivity based on FDA information, meaning it could be one of the first generic versions to reach patients. The launch strengthens Natco's oncology and specialty portfolio in the U.S.
This is a positive development for shareholders — a first-to-market generic entry into a multi-billion-dollar U.S. drug opens a meaningful new revenue stream and could boost near-term earnings, especially during the 180-day exclusivity window. It reinforces Natco's positioning as a key player in complex oncology generics abroad.